Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Background: High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above; however, in most countries, high-dose vaccines are not widely implemented. Assessing the relative effectiveness of high-dose compared to standard-dose...

Full description

Bibliographic Details
Main Authors: Biering-Sørensen, T. (Author), Claggett, B.L (Author), Gislason, G.H (Author), Jensen, J.U.S (Author), Johansen, N.D (Author), Køber, L. (Author), Krause, T.G (Author), Landray, M.J (Author), Larsen, C.S (Author), Modin, D. (Author), Nealon, J. (Author), Salamand, C. (Author), Samson, S. (Author), Sivapalan, P. (Author), Solomon, S.D (Author), Valentiner-Branth, P. (Author), Vestergaard, L.S (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Feasibility
Influenza
Pneumonia
Pragmatic
Randomized controlled trial
Registry
Vaccine
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items